Pharmaceutical Supply – Clindamycin Hydrochloride Capsules

The contract entails the manufacture and delivery of Clindamycin Hydrochloride Capsules to meet stringent FDA current Good Manufacturing Practices and Defense Logistics Agency standards for deployment aboard a military vessel. The product must adhere to all regulatory requirements for quality, potency, and safety, ensuring suitability for use in military medical operations. Production will comply with the NAICS code 325412, which classifies pharmaceutical preparation manufacturing, and the contract operates under the broader oversight of the Department of Defense through the Defense Logistics Agency. Delivery is structured to support operational readiness, with the capsules destined for use on a naval vessel, necessitating precise packaging, labeling, and shipment protocols aligned with military logistics demands. Although specific quantities, timelines, and delivery locations are not detailed, the contract’s linkage to a designated military delivery identifier and its issuance under a federal subcontract framework indicate a formalized, high-priority procurement. The solicitation was posted in July 2026, suggesting future performance, and the contractual obligations are governed by federal procurement regulations applicable to defense supply chains, including compliance with traceability, inspection, and documentation requirements throughout the supply lifecycle.